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Summary Between 1974 and 1984 69 adults with acute lymphoblastic leukaemia (ALL) were treated with
two different protocols. Fifty-four (78%) of the patients entered complete remission (CR); 27 of these then
received a consolidation protocol consisting of daunorubicin, cytosine arabinoside and 6-thioguanine,
followed by two courses of intravenous methotrexate 500 mgm2 with folinic acid rescue. All patients
received intrathecal methotrexate and cranial irradiation (24Gy) followed by maintenance therapy with
6-mercaptopurine and methotrexate for at least 2 years. The median survival for all patients was 23 months
from the time of presentation with an actuarial 5-year survival of 21%. The actuarial chance of surviving
5 years in CR for patients receiving the consolidation protocol was 38% compared to 19% for patients
receiving no consolidation (P=NS). Only patient age and white cell count at presentation were found to
influence the chance of achieving CR and the chance of overall survival. The presence or absence of c-ALL
antigen did not influence prognosis. Patients younger than 35 years with low white cell counts at presentation
(< O x 1091-1) had a particularly good prognosis but no patient with T-ALL and no patient older than 50
years old at diagnosis survived more than 18 months.
In children with acute lymphoblastic leukaemia
(ALL) survival is adversely affected by a number of
features at presentation including high white cell
count (WBC), age over ten years, male sex, and the
presence of a mediastinal mass (Simone et al., 1975;
Chessells et al., 1981). Anaemia, thrombocytopenia,
the absence of the common c-ALL antigen
(CALLA) and the morphological FAB subtype L2
have also been shown to be associated with poor
prognosis (Greaves et al., 1981; Sallan et al., 1980).
The overall five year survival in children is 50%
(Chessells et al., 1977; Hagbin et al., 1980) although
some centres using more intensive protocols report
better results (Henze et al., 1982; Lampert et al.,
1984).
The outlook for adults with ALL is worse than
that of younger patients. In adults the 5-year
survival is <30% in most series (Lister et al., 1978;
Jacobs & Gale, 1984; Henderson et al., 1979).
Furthermore it is not clear whether the adverse
prognostic features in childhood leukaemia also
apply to adults, or whether intensive consolidation
therapy given in remission will improve prognosis.
In this paper we report the results of treating adults
with ALL with two sequential protocols used
between 1974 and 1984. We correlated their
response to treatment with specific features at
presentation.
Materials and methods
Patients
Sixty-nine patients, 46 men and 23 women, aged
from 16-66 years (mean 30.2 years) were treated
over the 10-year period 1974 to 1984. The diagnosis
was based on the examination of the blast cells in
Romanowsky stained films and cells were classified
according to the criteria of the FAB group (Bennett
et al., 1981). Cytochemical stains for Sudan black,
myeloperoxidase, PAS and acid phosphatase were
also carried out. Terminal deoxynucleotidyl
transferase was measured initially by a biochemical
assay and later by immunofluorescence (Bollum,
1979), Cell surface marker studies were performed
as follows: T-cell ALL was diagnosed initially on
the basis of E-rosetting with sheep red cells and
more recently by specific anti-T cell monoclonal
antibodies. The presence of the CALLA was
assessed initially by heterologous antiserum
(Greaves et al., 1975) and later by the J5 mono-
clonal antibody (Ritz et al., 1980). Specific anti-
human immunoglobulin sera were used to make the
diagnosis of B-cell ALL.
The pre-treatment clinical and haematological
characteristics for all patients are summarised in
Table I. The incidence of the FAB L2 subgroup
increased with age (Figure 1); L2 morphology was
found in 27 of the 49 patients below the age of 35
(58%) and in 13 out of 18 patients over 35 (77%)
(P<0.05). There was no significant relationship
between the proportion of patients with common-
ALL antigen (CALLA) positive cells and age.
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Table I Patient characteristics and response to treatment.
Median
survival
(months)
No. CR(%) Remitters All
ALL 69 54 (78) 21 23
Sex
M 46 35 (76) 22 22
F 23 19 (83) 23 24
WBC count at presentation (x l0O l-l
0-10 31 28 (90) 26 29
11-100 23 16 (69)' 22 18a
100+ 15 10 (66) lib 12b
AGE (years)
>50 11 2 (18) 6 6
<50 58 54 (90)b 24b 26b
FAB class
LI 26 24 (92) 21 25
L2 40 27 (68)' 22 20
L3 1 1 (100) 3 4
Phenotype
CALLA
+VE 36 (66) 28 (78) 21 25
-VE 13 (19) 8 (61) 23 18
T-ALL 5 (9) 4 (80) 9a 8
Therapy trial
Standard
ALL 36 27 (74) 20 19
ALL+DAT 33 27 (78) 21 26
ap<oo5 bp<0.01.
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Treatment protocols
A. Protocol in usefrom 1974 to 1978
Induction Vincristine (1.4mgm 2, max. 2mg) and
prednisolone (40mgm-2).
Consolidation L-asparaginase (10000 um-2) or
cyclophosphamide (600mgm-2 X 1) with vincristine
(1.4mgm-2 X 1) cytosine arabinoside (100 mgm-2)
daily and prednisolone (40 mgm-2) daily for 5 days
(COAP).
Maintenance Continuous methotrexate (15mgmg-2
daily for 3 to 5 days and 6-mercaptopurine
(70mgm 2) for 2 years with precise dosage
adjusted in accordance with the blood counts.
B. Protocol in usefrom 1978 to 1982
Induction Vincristine and prednisolone with L-
asparaginase as above.
Consolidation Daunorubicin 50mgm-2 daily for 3
days, cytosine arabinoside 100mgm-2 for 7 days,
6-thioguanine 150mgm-2 for 7 days (DAT)
followed by methotrexate 500mgm-2 with folinic
acid rescue repeated on a second occasion after
peripheral blood recovery.
Maintenance Continuous methotrexate and 6-
mercaptopurine as above for 2 years with re-
induction every 12 weeks with vincristine
(1.4mg/weekly x 3) and prednisolone 40mgm-2 for
3 weeks.
C. Protocol in usefrom 1982 to 1984
Induction Vincristine, prednisolone and L-
asparaginase with adriamycin 50mgm2 weekly for
3 weeks and cyclophosphamide 600mgm-2 weekly
for 3 weeks.
Consolidation DAT foll
methotrexate x 2 as above.
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Figure 1 Distribution of the two major FAB types of
ALL in relation to the patients' age at presentation
(A) LI; ([1) L2.
There was no correlation between the phenotype of
the blast cells (CALLA+ or CALLA-) and
morphology (FAB LI or L2).
[owed by high dose
Maintenance As per 1978-1982 schedule above
plus adriamycin 50 mg m 2x 1 and cyclophospha-
mide 750mgm-2x1 as part of 12 weeks re-
induction cycle.
All patients received central nervous system
prophylaxis with fractionated cranial irradiation
(24Gy) and intrathecal methotrexate (10mgm-2,
12mg maximum) on eight occasions.
Patients are divided into two treatment groups
for the purpose of this analysis: (A) those who
received standard ALL therapy (1974-1978) (n =27)
and (B) those who received DAT consolidation
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therapy and high dose intravenous methotrexate
(1978-1984) (n=27).
Statistical methods
Survival and remission curves were calculated by
means of standard life table techniques (Kaplan &
Meier, 1958). Statistical significance was determined
by the log rank method (Peto et al., 1977). The
significance of prognostic factors in determining the
duration of overall survival and of CR was
evaluated by stepwise logistic regression methods
using Cox's proportional hazards model (Cox,
1972).
Results
Remission induction rates
Fifty-four (78%) of the patients entered CR,
including four of the five patients with T-ALL. The
CR rate decreased with age: only two of the 11
patients over the age of 50 years and only nine of
the 18 patients older than 35 years achieved CR
(P<0.01). The 15 patients who did not achieve CR
all died within 6 months of presentation either with
resistant disease or from infection. There was no
difference in CR rates between the two treatment
groups or between men and women. Twenty-eight
(90%) out of 31 patients with presenting WBC
counts less than 10 x IO0 1 1 entered CR whereas
only 26 out of 38 (69%) patients with higher
presentation WBC counts entered CR (P<0.05).
Twenty-four out of 26 patients (92%) with LI
morphology entered CR compared to 28 out of
42 (68%) with L2 morphology (P<0.05). No
differences were recorded in CR rate between
CALLA +ve and CALLA -ve patients.
Survival ofpatients in CR
The median survival for all patients entering CR
was 23 months. The median follow-up time is 76
months with 32% of patients remaining in
continuous CR (Figure 2). No patient who
remained in first CR for more than 5 years has
subsequently relapsed. Of the 34 patients who
relapsed 31 died within 1 year of relapse regardless
of whether or not a second CR was achieved. There
are three long-term survivors in second or third
remission more than 1 year after first relapse. The
four patients with T-ALL who entered CR all
relapsed and died within 1 year of entering CR.
The one patient with L3 ALL entered CR but
relapsed with CNS disease within 3 months and
died with CNS and bone marrow relapse. For
patients in CR there were no significant differences
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Figure 2 Actuarial disease-free survival for the 54
patients who achieved complete remission. The plateau
is at 32%. Diagonal marks represent individual
patients who survive in CR.
in duration of CR between patients with LI or L2
morphology, CALLA+ or CALLA- phenotype,
aged less or greater than 35 years or between men
and women.
Patients with the lowest presenting white cell count
had the best outlook after achieving CR. Patients
with presenting WBC counts <10 x IO 1-1 had a
median duration of CR of 26 months compared to
22 months for patients presenting with WBC
count between 10 and 100 x IO9 1- and 11 months
for patients presenting with WBC counts >I00 x
10.91 1 (P<0.01) (Figure 3).
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Figure 3 Actuarial disease-free survival for the 54
patients who achieved CR analysed by WBC count at
presentation. Diagonal marks represent individual
patients who survive in CR. WBC ( x I091-1)O10(-----)
n=28; 11-100( ) n=16; 100+( ) n=10. P<0.05.
Factors influencing overall survival
The median survival for all patients from the date
of presentation was 23 months with median follow-
up of 77 months. The factors at presentation that
influence survival can be divided into two
categories: those that affect the chances of attaining
CR, and hence influence survival but have no
relevance once CR has been achieved, and those
that are relevant both to the achievement of and
survival after CR.
Two factors of the first type were found, namely
age and blast cell morphology. Patients under the
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age of 35 survived longer than older patients
(P<0.01, Figure 4), as did patients with LI
morphology when compared to L2 morphology
(P<0.05). However, the significance of the
influence of morphology was not confirmed by
multivariate analysis, which found age to be the
more dominant factor, and explains the survival
advantage for the LI patients as due to their
younger mean age. There were no long-term
survivors among patients presenting over the age of
50 years.
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Figure 4 Actuarial survival for all 69 patients
analysed by age at presentation. Diagonal marks
represent surviving patients. ( ) 15-35y, n=51; (-
35-66y, n=18. P<0.01.
Only WBC at presentation influenced survival by
affecting both the chance of achieving CR and the
survival after CR was attained.
Forty-one percent of patients with the lowest
WBC count (<10 x 10.9 -') remained in con-
tinuous CR at the time of writing compared to
under 20% for all patients presenting with WBC
count >10 x 10.9l-1 (P<0.05). It is possible to
identify a subgroup of patients under the age of 35
years with presenting WBC counts of
<10 x I09 -' who had an overall median survival
from the time of diagnosis of 32 months and an
actuarial five year survival of 42% compared to 23
months and 21% respectively for all other patients
(P<0.05). The independent effects of age and white
cell count on survival was established by multi-
variate regression analysis. The surface phenotype
(CALLA+ve or CALLA-ve) was not found to
influence the duration of CR in this series.
Effect ofconsolidation chemotherapy
Twenty-seven patients received standard
consolidation therapy and 27 intensive therapy in
remission. There was no difference in the
pretreatment characteristics of the two groups, and
no difference in the overall CR rates (Table II). The
median disease-free survival was 20 months for
patients receiving standard consolidation therapy
and 21 months for patients receiving intensive
Table II Characteristics of patients receiving two
treatment protocols.
Patients receiving Patients receiving
DAT consolidation standard ALL therapy
Sex
M 19 (57%) 27 (75%)
F 14 (43%) 9 (25%)
Mean WBC
( x 1091-') 43 (0-96) 69 (1-160)
Mean age (y) 31 (15-66) 30 (16-64)
FAB subtype
LI 11 (36%) 15 (58%)
L2 19 (64%) 21 (42%)
CALLA
+VE 22 (81%) 14 (64%)
-VE 5 (19%) 8 (36%)
Total 27 (50%) 27 (50%)
There was no statistically significant difference between
any of the patient pretreatment characteristics for the two
treatment protocols.
therapy. The predicted actuarial chances of
remaining in CR (Figure 5) at 5 years were 18%
(standard chemotherapy) and 38% (intensive
consolidation) with median follow-up times of 93
and 34 months respectively (P=NS).
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Figure 5 Actuarial disease-free survival for 54 patients
who achieved CR analysed by type of consolidation
and/or maintenance chemotherapy in remission.
Diagonal marks represent patients surviving in CR.
DAT consolidation, n=27; (- ) standard
ALL therapy, n=27. P=n.s.
Discussion
Most protocols used to treat adults with ALL are
based on the regimens employed with success in
childhood, but despite the achievement of CR in
the majority of cases most adults with ALL relapse
and die within 4 years. This contrasts with the long
disease-free survival seen in children (Jacobs &
Gale, 1984). The CR rate in the patients reported
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here is similar to those reported in several recent
studies (Baccarani et al., 1982; Hoelzer et al., 1984;
Schauer et al., 1983; Aviles et al., 1983; Gottlieb et
al., 1984). Lower CR rates were observed in older
patients and those with high presenting WBC
counts.
Early intensive consolidation has been reported
to improve survival in children (Henze et al., 1982;
Lampert et al., 1984) and our own programme of
DAT consolidation given early in remission was
designed to achieve similar benefit in adults. In the
event a minor improvement was observed in the
actuarial survival with the more intensive regimen,
but this was not significant. Longer-term follow-up
and larger numbers of patients are needed to enable
firm conclusions to be drawn.
Univariate analysis of the individual patient
characteristics suggested that L2 morphology,
increasing age and high WBC influence the chances
of entering CR and of survival. The multivariate
analysis showed, however, that the adverse effect of
L2 morphology could not be separated from the
effect of age. There are conflicting reports on the
prognostic significance of the morphological
subtype (Leiment et al., 1980; Brearley et al., 1975)
and the influence of age may be more important.
This analysis further showed that age at diagnosis
and white cell count are the only two variables to
influence survival at the time of presentation. For
patients who achieved CR only the WBC at
presentation had an effect on outcome; we found
that the log 10 of the leucocyte count at
presentation had the greatest influence on survival.
This suggests that it is the tumour burden at the
time of diagnosis which affects the chance of long-
term survival. These findings are similar to other
recently reported series (Mertelsman et al., 1982).
Hoelzer and co-workers have shown that disease-
free survival in their patients with T-ALL was
comparable to that seen in patients with common
ALL (Hoelzer et al., 1984) but this was not our
experience with smaller numbers of patients.
We identified a subgroup of patients under the
age of 35 with presenting WBC less than
10 x IO91- ' who have a particularly favourable
outlook with conventional chemotherapy; this may
improve further with more intensive treatment
regimens. It might not therefore be appropriate to
offer to this group of patients allogeneic bone
marrow transplant (BMT) in first remission in view
of the relatively high mortality of BMT and the
relatively high relapse rates for those who survive
the procedure (Barrett et al., 1985). More intensive
induction therapy may benefit older patients in
whom CR rates were low, since their survival once
in remission was not affected by age. Those patients
presenting with a higher WBC than 10 x IO91-'
had a poor prognosis, whether or not CR is
achieved. Improved survival might be obtained by
intensification both of induction and consolidation
therapy. The prognosis in those young patients
whom we have defined as having a particularly
poor outlook could perhaps be improved by allo-
grafting or by autografting in first remission.
We conclude that the accurate identification of
the different prognostic groups in adult ALL, which
seem to differ from those in children, should
facilitate selection of the appropriate treatment and
improve the long-term outlook.
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